9 Meters Biopharma, Inc.
NMTRQ
$0.00
$0.000.00%
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.99M | 1.95M | 2.42M | 3.65M | 3.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.79M | 10.74M | 8.72M | 11.20M | 11.36M |
| Operating Income | -12.79M | -10.74M | -8.72M | -11.20M | -11.36M |
| Income Before Tax | -13.87M | -11.93M | -9.35M | -11.13M | -11.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.87M | -11.93M | -9.35M | -11.13M | -11.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.87M | -11.93M | -9.35M | -11.13M | -11.35M |
| EBIT | -12.79M | -10.74M | -8.72M | -11.20M | -11.36M |
| EBITDA | -12.79M | -10.74M | -8.71M | -11.19M | -11.36M |
| EPS Basic | -1.02 | -0.92 | -0.72 | -0.86 | -0.88 |
| Normalized Basic EPS | -0.62 | -0.57 | -0.45 | -0.54 | -0.55 |
| EPS Diluted | -1.02 | -0.92 | -0.72 | -0.86 | -0.88 |
| Normalized Diluted EPS | -0.62 | -0.57 | -0.45 | -0.54 | -0.55 |
| Average Basic Shares Outstanding | 13.59M | 13.00M | 12.96M | 12.95M | 12.91M |
| Average Diluted Shares Outstanding | 13.59M | 13.00M | 12.96M | 12.95M | 12.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
